# c-KIT joins the TSC ToolKIT: a new driver of renal cystogenesis

## TL;DR

A new study identifies c-KIT as a key driver of kidney cyst formation in Tuberous Sclerosis Complex, suggesting it could be a new target for treatment.

## Contribution

The study reveals c-KIT as a novel driver of renal cystogenesis in TSC, offering a new therapeutic approach.

## Key findings

- c-KIT is identified as a pivotal driver of renal cyst formation in Tuberous Sclerosis Complex.
- Pharmacologic inhibition of c-KIT could complement existing mTOR-targeted therapies for TSC.

## Abstract

Tuberous Sclerosis Complex (TSC) is a multisystem disorder marked by benign tumors in brain, lung, and kidney. While the loss-of-function mutations in TSC1 or TSC2 have been known for decades, the molecular basis that converts these mutations into cystic kidney lesions has remained elusive. In this issue of EMBO Molecular Medicine, Zahedi and colleagues now uncover an unexpected culprit: the proto-oncogene receptor tyrosine kinase c-KIT. Their work identifies c-KIT as a pivotal driver of renal cystogenesis in TSC and suggests that its pharmacologic inhibition could complement existing mTOR-targeted therapy.

M. Mollapour and colleagues discuss the role of the proto-oncogene receptor tyrosine kinase c-KIT in Tuberous Sclerosis Complex (TSC) renal cystogenesis, as reported by M. Soleimani and colleagues, in this issue of EMBO Mol Med.